GYRE THERAPEUTICS, INC. (NASDAQ:GYRE) reported executive stock activity on June 11, 2026, when Chief Operating Officer Ye Weiguo sold 2,800 shares of common stock. The transaction, valued at $17,276, involved shares sold at a weighted average price of $6.17, with the execution occurring within a narrow price band of $6.16 to $6.18 per share. Following the disposition, Mr. Ye retained a direct holding of 700,000 shares of GYRE common stock.
The sale activity was preceded on the same day by the acquisition of 2,800 shares through the exercise of fully vested stock options. These options carried an exercise price of $0.75 per share, providing a significant cost differential compared to the subsequent market sale.
This executive activity unfolds against a backdrop of substantial corporate developments for Gyre Therapeutics. The company recently received confirmation from China's National Medical Products Administration regarding the acceptance of its New Drug Application for F351, a therapeutic candidate targeting chronic hepatitis B-induced liver fibrosis. The regulatory authority has granted priority review status to the application, indicating an expedited evaluation pathway for the treatment.
Concurrently, Gyre Therapeutics finalized its acquisition of Cullgen Inc., a clinical-stage biopharmaceutical enterprise. The transaction was structured as an all-stock deal valued at approximately $300 million. As part of the integration, Dr. Ying Luo, formerly the Chief Executive Officer of Cullgen, has assumed the roles of President and CEO of Gyre Therapeutics and joined the company's Board of Directors. Ping Zhang continues in his capacity as Chairman of the Board.
Market data indicates that GYRE stock closed at $5.86, reflecting a 16% decline year-to-date. Analysis suggests the stock exhibits high volatility, with a beta coefficient of 4.92 recorded. Some evaluations indicate the stock may be overvalued at current price levels, though such assessments reflect specific analytical frameworks.
The insider transaction details were formally disclosed through a Form 4 filing submitted to the Securities and Exchange Commission on June 15, 2026. The filing provides the official record of the executive's stock movements and current holdings.
The biopharmaceutical sector continues to navigate complex regulatory environments and consolidation trends. Gyre Therapeutics' expansion through acquisition and its regulatory progress in China highlight strategic efforts to strengthen its pipeline and leadership structure. However, the company faces near-term market volatility and valuation considerations that may influence investor sentiment.